Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24472
NL-OMON24472
Completed
Not Applicable

Prevention of (re)hospitalisation for heart failure and/or mortality by an intensive, protocolised intervention by both a clinician and a cardiovascular nurse in a country with a primary care-based health care system. system ( the Netherlands).

Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.0 sites240 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.
Enrollment
240
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Bruggink-Andre de la Porte PW, Lok DJ, van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen DJ, Hoes AW. Related Articles, Links.
Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study.
Eur J Heart Fail. 2005 Aug;7(5):910-20. Review.
PMID: 16087143 [PubMed - indexed for MEDLINE].

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.

Eligibility Criteria

Inclusion Criteria

  • •The following are required at screening visit:
  • •1\. In – or out hospital patients with congestive heart failure New York Heart Association Functional Class III and IV;

Exclusion Criteria

  • •1\. Severe dementia or serious psychiatric illness;
  • •2\. Discharge to a nursing home;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Prevention of rehospitalization for heart failure by using LAVITA at home in elderly patients with repeated heart failure hospitalizations
JPRN-jRCT1030220584ishi Isao20
Unknown
Phase 3
How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)Heart Failure Acute
NCT04080388Hillel Yaffe Medical Center200
Completed
Not Applicable
Self-Management and Care of Heart Failure With Group Clinics (SMAC-HF)Heart Failure, Congestive
NCT00439842Carol Smith, RN, PhD, FAAN198
Completed
Not Applicable
Self-care Intervention for Reducing Rehospitalization for Heart Failure: a Randomized Clinical Trial (SIHF)Heart Failure
NCT04870918Instituto de Cardiologia do Rio Grande do Sul60
Completed
Not Applicable
Early Care After Discharge of HF PatientsHeart Failure
NCT01820780Assistance Publique - Hôpitaux de Paris507